Posaconazole: Difference between revisions
From IDWiki
No edit summary |
(→) |
||
| Line 78: | Line 78: | ||
|[[Candida krusei]] |
|[[Candida krusei]] |
||
|0.5 |
|0.5 |
||
| + | | |
||
| − | | colspan="4" | |
||
| + | | |
||
| − | | colspan="4" | |
||
| + | | |
||
| + | | |
||
| + | | |
||
| + | | |
||
| + | | |
||
| + | | |
||
|- |
|- |
||
|[[Candida lusitaniae]] |
|[[Candida lusitaniae]] |
||
Revision as of 21:55, 19 January 2021
Therapeutic Drug Monitoring
- Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption
- For prophylaxis, target trough >0.7 mg/L, or random level 0.35 mg/L 48 h after starting therapy
- For treatment, target trough >1 mg/L
Clinical Breakpoints
| Species | ECV (μg/mL) | Breakpoints (μg/mL) | Breakpoints (mm) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| S | SDD | I | R | S | SDD | I | R | ||
| Candida albicans | 0.06 | ≤0.06 | ≥0.12 | ||||||
| Candida dubliniensis | |||||||||
| Candida glabrata | 2 | ||||||||
| Candida guilliermondii | 0.5 | ||||||||
| Candida kefyr | 0.25 | ||||||||
| Candida krusei | 0.5 | ||||||||
| Candida lusitaniae | 0.12 | ||||||||
| Candida parapsilosis | 0.25 | ≤0.06 | ≥0.12 | ||||||
| Candida tropicalis | 0.12 | ≤0.06 | ≥0.12 | ||||||
| Cryptococcus neoformans | |||||||||
| Cryptococcus gattii | |||||||||
